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Background: Approaches to prostate cancer (PCa) care have changed in recent years out of concern for
overdiagnosis and overtreatment. Despite these changes, many patients continue to undergo some form
of curative treatment and with a growing perception among multidisciplinary clinicians that more
aggressive treatments are being favored. This study examines patterns of PCa care in Australia, focusing
on current rates of screening and aggressive interventions that consist of high-dose-rate (HDR)
brachytherapy and pelvic lymph node dissection (PLND).
Methods: Health services data were used to assess Australian men undergoing PCa screening and
treatment from 2001 to 2014. Age-speciﬁc rates of prostate-speciﬁc antigen (PSA) screening were
calculated. Ratios of radical prostatectomy (RP) with PLND to RP without PLND, and HDR brachytherapy
to low-dose-rate (LDR) brachytherapy were determined by state jurisdictions.
Results: From 2008, the rate of PSA screening trended downward signiﬁcantly with year for all age
ranges (P < 0.02) except men aged  85 (P ¼ 0.56). PLND rates for 2008e2014 were lower than rates for
2001e2007 across all states and territories. From 2008 to 2014, PLND was performed  2.7 times more
frequently in New South Wales and the Australian Capital Territory than in other jurisdictions. Since
2007, brachytherapy practice across Australia has evolved towards a relatively low use of HDR brachy-
therapy (ratio of HDR to LDR brachytherapy < 0.5 for all jurisdictions except the Australian Capital
Territory).
Conclusion: Rates of PLND and HDR brachytherapy for PCa have declined in Australia, providing evi-
dence for the effect of stage migration due to widespread PSA screening. Currently, PSA screening rates
remain high among older men, which may expose them to unnecessary investigations and treatment-
related morbidity.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The prostate cancer (PCa) landscape has been transformed over
the past decade with a focus on limiting overdiagnosis and
reducing overtreatment. In particular, the use of mainstay curative
treatments, such as radical prostatectomy (RP) and radiotherapy,
for low-risk men has been questioned because of the signiﬁcant
morbidity,1 quality-of-life impact,2 and economic burden3 associ-
ated with these treatments. PCa care has been further transformed
by the emergence of active surveillance, which aims to delay orepartment of Surgery, Austin
c 3084, Australia.
entschuk).
ciﬁc Prostate Society, Published bprevent treatment by closely monitoring disease progression.
Active surveillance is an effective option for men with localized
PCa1 and, encouragingly, active surveillance uptake from a state-
based registry of Australian PCa patients has been shown to be
higher than inmany international registries.4Widespread prostate-
speciﬁc antigen (PSA) testing has resulted in increased PCa detec-
tion, as well as a ‘stagemigration’ towards an earlier diagnosis and a
reduced incidence of metastatic disease.5,6 This has led to growing
concern for the overdiagnosis in younger men at low risk of clini-
cally signiﬁcant disease7 and older men at low prostate-speciﬁc
mortality risk.8
Despite these transformations in PCa care, a majority of men
with newly diagnosed PCa undergo some form of curative treat-
ment, regardless of their disease risk.5 Additionally, studies exam-
ining the impact of uro-oncology multidisciplinary meetings overy Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Fig. 1. The graph shows the ratio of radical prostatectomy (RP) with pelvic lymph node
dissection (PLND) to RP without PLND across state jurisdictions between 2001e2007
and 2008e2014 (all years inclusive). The ratio of the Australian Capital Territory for
2001e2007 (black) exceeds the maximum y-axis.
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terventions for PCamanagement.9,10 This includes a greater volume
of high-dose-rate (HDR) brachytherapy,10 which is used primarily
as ‘boost’ therapy [with either external beam radiotherapy (EBRT)
or surgery] for higher-risk PCa than what is typically treated with
low-dose-rate (LDR) brachytherapy.5 Furthermore, there is the
potential for an increased uptake of pelvic lymph node dissection
(PLND), the most reliable and accurate staging method for prostate
cancer metastases.11 Therefore, the objective of our current study
was to analyze for temporal trends in these key indicators of PCa
care, in particular, the rates of screening and aggressive in-
terventions for PCa.
2. Materials and methods
2.1. Study population
The study population consisted of all Australian men who un-
derwent a screening PSA test, RP, or brachytherapy for PCa between
2001 and 2014. The study period commenced from when a dedi-
cated PSA screening test was ﬁrst incorporated into the Australian
Government's Medicare Beneﬁts Schedule (MBS) in 2001.
2.2. Data selection
A number of studies have analyzed the impact of uro-oncology
multidisciplinary meetings on PCa management decisions over the
past decade. Notable trends have been: (1) a shift towards greater
active surveillance of lower risk disease;10 and (2) the utilization of
aggressive interventions, such as HDR brachytherapy.9,10 The pre-
sent study uses health services data to analyze trends in PSA
screening and aggressive interventions. Future registries will be
able to account for the number and characteristics of men on active
surveillance.12
2.3. Data extraction
Data on services deﬁned by speciﬁc item numbers were sourced
from the MBS website.13 This captures all tests and treatments
performed in the community. Delivery of HDR brachytherapy to the
prostate uses the MBS billing code of ‘37227’ and was ﬁrst intro-
duced to the MBS in 2007. HDR brachytherapy must be performed
‘by a urologist or radiation oncologist’ in ‘association with a radi-
ation oncologist’, with no limitations on tumor staging or grade.
Counts of HDR brachytherapy include both the insertion and
removal of catheters for radiation delivery. Seed implantation of
low-dose-rate brachytherapy has been billed under code ‘37220’
since 2001, and must also be performed in ‘association with a ra-
diation oncologist’. LDR brachytherapy is restricted to patients with
localized PCa, Gleason  7 (Gleason  6 prior to 2008) and
PSA  10 ng/mL at the time of diagnosis. Only LDR brachytherapy
data from 2007 were analyzed to enable comparisons with HDR
brachytherapy over the same time period.
A dedicated item code (‘66655’) for an initial ‘screening’ PSA test
was introduced in 2001 and is deﬁned as a single PSA test per-
formed during a 12-month period in previously undiagnosed
prostatic disease. Radical prostatectomy with ‘sparing of nerves
around the bladder and bladder neck reconstruction’ is billed under
code ‘37211’ when PLND is performed or ‘37210’ when PLND
omitted. Both RP item codes were introduced prior to 2001. EBRT
was excluded from this study because of different radiation ﬁeld
settings and dosimetry, along with poor capture of the actual
treatment received when using MBS item codes.14 All population
data were obtained from the Australian Bureau of Statistics.152.4. Statistical analysis
Age-speciﬁc rates of PSA-based screening were calculated
from 2001 to 2014. Trends of annual change in PSA screening
rates from 2008 were analyzed using Cuzick's nonparametric test
for trend. Mean 7-year ratios (2001e2007 and 2008e2014) of RP
with PLND compared to RP without PLND were determined for
state jurisdictions. Annual ratios of HDR brachytherapy to LDR
brachytherapy were determined for state jurisdictions from
2007.3. Results
3.1. Radical prostatectomy
The average annual Australian male population was 10,529,409
between 2001 and 2014. A total of 64,824 RPs were performed over
this period, of which 36,829 involved a PLND. The mean ratio of RP
with PLND to RPwithout PLND from 2001 to 2007 and 2008 to 2014
for each state jurisdiction is shown in Fig. 1. Overall, PLND was
performed more often than not, however, there was a considerable
decrease between 2001 and 2007 (when the mean ratio of RP with
PLND to RP without PLND was 1.9) and between 2008 and 2014
(when the same ratio was 1.1). This reduction in rate of PLND
occurred for all state jurisdictions. From 2008 to 2014, relatively
high rates of PLNDwere recorded in the Australian Capital Territory
(ACT) (mean ratio of 5.6) and New South Wales (NSW) (mean ratio
of 2.3), whereas rates were relatively low (< 0.9) across all other
jurisdictions.3.2. Brachytherapy
Between 2007 and 2014, 2,326 HDR brachytherapy pro-
cedures (either implant insertion or removal) were performed
across Australia. Most cases arose from NSW (1,123), Queensland
(512), Western Australia (357), Victoria (191), and South Australia
(77). Between 2007 and 2014, 5,060 LDR brachytherapy im-
plantation procedures were performed, with most occurring in
Victoria (1,555), NSW (1,163), Queensland (1,111), South Australia
(673), Western Australia (317) and Tasmania (201). The ratio of
HDR to LDR brachytherapy across state jurisdictions is shown in
Fig. 2.
Fig. 2. The graph shows the ratio of high-dose-rate (HDR) brachytherapy to low-dose-
rate (LDR) brachytherapy from 2007 to 2014. The ratio of the Australian Capital
Territory for 2013e2014 exceeds the maximum y-axis.
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PSA screening rates have been highest for patients aged
65e74 years (an annual average of 21,453 per 100,000 men) and
55e64 years (19,575 per 100,000 men) from 2001 to 2014, which
together accounted for 56% of all screening tests over this period
(Fig. 3). The next highest screening rates were for patients aged
75e84 years (15,793 per 100,000 men), 45e55 years (12,315 per
100,000 men) and  85 years (8,064 per 100,000 men). From 2008,
PSA screening rates trended downward signiﬁcantly year-to-year
for all ranges (P < 0.02) except for men aged  85 years
(P ¼ 0.56), and excluding a small aberrant rise in 2011.4. Discussion
The key ﬁndings of this population-based analysis are that a
considerable decline in PLND and HDR brachytherapy rates
occurred over the study period. This trend was observed across all
Australian states and territories, excluding brachytherapy rates in
the Australian Capital Territory. Together these results indicate that
fewer Australian men are undergoing aggressive interventions for
PCa. Previous United States (US) studies16,17 have observed a similar
decline in PLND rates and this was attributed to stagemigration and
an improved ability to risk-stratify patients before surgery. Stage
migration of PCa that has been observed in a number of AustralianFig. 3. The graph shows age-speciﬁc rates of PSA screening tests per 100,000 men for
combined states and territories since 2001. PSA, prostate-speciﬁc antigen.studies5,6 is a highly feasible explanation for our result. We suspect
that more patients are being diagnosed with organ-conﬁned and
lower risk disease as a result of PSA testing, which has reduced the
need for aggressive interventions. Risk-stratifying tools, or nomo-
grams, that are based on routinely available preoperative variables
have been shown to better identify men at risk of nodal disease18
and are currently used in Australian institutions.19 Notably, many
of these risk-stratifying tools are based on a limited PLND, which
may underestimate the incidence of positive nodes, and none have
had oncologic efﬁcacy veriﬁed with a prospective randomized
clinical trial.11
In the past few decades, PCa treatment planning has become
more complicated and contentious owing to the proliferation of
treatment options and an absence of high-quality evidence sup-
porting one method over another.2 Consequently, multidisciplinary
teams often decide on and coordinate clinical treatments,9 which
may involve a number of modalities for an individual patient.
Technical advances and the publication of trial results are two
major reasons multidisciplinary clinicians will choose to treat pel-
vic nodes and to recommend particular therapies.20 Brachytherapy
has been an established technique since the commencement of our
study period. Conversely, prostate surgery has seen the rapid
adoption of a minimally invasive, robot-assisted technique.3
Currently it is unclear to what effect a shift from an open to a
minimally invasive approach has had on the use of PLND.21,22 Sur-
geon experience is one important determinant for the likelihood of
performing PLND, irrespective of the surgical approach, and this
likely reﬂects the increased risk of complications with PLND, such
as lymphedema, lymphocele, deep vein thrombosis, and pulmo-
nary emboli.21
Although local registry and health services data have shown that
RP incidence is rising for Australian populations,5,23 to our knowl-
edge, patterns of PLND have not previously been explored. We
found that PLND rates during prostate surgery greatly varied
amongst Australian state jurisdictions despite overall widespread
reductions. For example, between 2008 and 2014, PLND rates in
NSW and the ACT were nearly three times higher than in other
jurisdictions. A subanalysis has shown that PSA screening rates in
NSW and ACT over this same period were within 10% of the annual
national average. Hence, the elevated PLND rates in NSW and ACT
compared to other jurisdictions were not simply due to these states
performing less screening and therefore treating higher-risk PCa.
More plausible explanations include the dissemination of robot-
assisted technology, as well as variable involvement of multidisci-
plinary teams and the adequacy and/or access to radiotherapy
centers.24
HDR brachytherapy uses a high dose of radioactive seeds
( 12 Gy/h) that can only be placed temporarily, compared with
permanent seed placement in LDR brachytherapy. Since 2007, we
have found a shift towards much lower use of HDR brachytherapy
relative to LDR brachytherapy. By 2014, all state jurisdictions,
except ACT, had a ratio of HDR to LDR brachytherapy of < 0.5.
Previous Australian registries have shown that HDR brachytherapy
is a minor contributor to overall PCa care2,5 and is used as either
adjunct therapy to androgen deprivation therapy or as boost ther-
apy with EBRT or surgery.5 Currently, HDR brachytherapy has not
been tested in sufﬁcient numbers to be recommended as mono-
therapy.11 Importantly, dosing and fractionation for HDR brachy-
therapy is inconsistently delivered across Australian radiotherapy
departments,25 which is unsurprising since no Australian guide-
lines exist and there is no clear consensus amongst international
brachytherapy societies.26,27
Another important ﬁnding of our study was that PSA-based
screening rates have signiﬁcantly declined since 2008 in all age
groups except for men aged  85 years (excluding a small aberrant
Lo et al / Patterns of prostate cancer care 23rise in 2011). Two large randomized trials have reported that mass
PSA-based screening offers limited beneﬁt or no beneﬁt over usual
care.28,29 Results of the European Randomised Study of Screening
for Prostate Cancer (ERSPC) showed screening did not affect all-
cause mortality after 11 years of follow-up but did show a
reduced incidence of advanced disease and prostate-speciﬁc mor-
tality in men aged 55e69.29 Thus far, urological societies have
discouraged widespread population screening but have endorsed a
role for opportunistic screening of men aged 55e69.11,30,31 We
found that the majority of screening tests are conducted in men
aged 55e74 and this potentially reﬂects the uptake of opportunistic
screening.
It is possible that the publication of the two major trials ques-
tioning the beneﬁts of screening and the resultant publicity affor-
ded to these studies32 have contributed to the reduction in
screening rates. Negative media reporting conceivably has alerted
patients to the limitations of screening and thereby inﬂuenced their
willingness to participate.32 Men aged 85 years may not have the
same access to contemporary online media sources, which poten-
tially explains the unchanged and unnecessarily high screening
rates amongst this age group. Another feasible explanation for the
reduction in screening rates in most age groups is the penetrance of
regional30 and key international guidelines32 such as the US Pre-
ventive Services Task Force. It will be interesting to see in time
whether the decline in PSA-based screening rates we recorded for
most age groups leads to a reversal of stage migration, such that
rates of advanced disease return towards pre-PSA era levels.
We could not be certain from the data available to us whether
patients undergoing PSA-based screening were asymptomatic or at
high suspicion for PCa (such as suspect digital rectal exam or family
history). A previous study of Australian men undergoing PSA-based
screening reported minimal prior symptoms for the majority of
men, suggesting that these may be true screening tests.33 It is
possible that incorrect item numbers were used for brachytherapy
(HDR or LDR) and prostate surgery (with or without PLND) in some
proportion of our data. It is also possible that PSA screening tests
were misclassiﬁed as monitoring or follow-up tests, each of which
have different item numbers. Medicare Australia performs ‘coning’
of multiple pathology items, whereby only the three most costly
items are reimbursed and recorded.8 Due to this approach, we may
have underestimated the true number of PSA screening tests.
Combination therapy is not currently recorded through health
services data and we suspect that androgen deprivation therapy
with HDR brachytherapy is widely used but not reported. Since
Medicare data does not presently capture the type of prostatectomy
approach, further studies are needed to determine if PLND rates
differ with a minimally invasive approach compared to a conven-
tional open prostatectomy. Additionally, we are unable to exclude
data for RPs (with or without PLND) performed in conjunctionwith
radical cystectomy for an invasive bladder tumor. A separate anal-
ysis of radical cystectomy (MBS billing code ‘37014’) has revealed
3,190 procedures were recorded for male patients between 2001
and 2014, which would account for < 5% of all RPs over this period.
We did not examine rates of focal therapy (not presently reim-
bursed by Medicare) or EBRT, which is poorly captured with
Medicare data.14 Notably, this study does not account for all men
undergoing aggressive interventions over the study period because
both androgen deprivation therapy (ADT) and EBRT can also be
used for higher risk disease. Our study has biases inherent with
observational data.
Although Medicare data have been validated to provide a true
account of prostate surgery and brachytherapy, accuracy can be
improved when combined with local registries.14 Local registries
also enable patient characteristics and cancer staging to be linked
to the treatment outcomes of PLND and HDR brachytherapy. An up-to-date analysis of clinical-decision making for aggressive in-
terventions, including the recommendations from multidisci-
plinary clinicians and use of risk-stratifying tools, as well as a
patient's beliefs and anxieties, would make a useful adjunct to our
study. Future studies should examine why PSA-based screening
rates remains relatively high among older men in Australia,
particularly because no speciﬁc guidelines currently exist for
managing a positive screening result in this age group.34
In conclusion, rates of PLND and HDR brachytherapy have
declined in Australia, which provides evidence for the effect of
stage migration from widespread PSA screening. Currently, PSA
screening rates among older men remain proportionately high,
which potentially exposes them to unnecessary investigations and
treatment. Our results reveal that contemporary approaches to
prostate surgery vary among jurisdictions and further investigation
is warranted to understand the clinical decision-making process
behind overall and regional trends.
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